If this message does not display properly, please click here to launch your browser
| Physician and Payer Perspectives on Emerging LABA/ICS Combinations in Asthma and COPD – Will New Treatments Differentiate Themselves from Advair and Symbicort? — A Webinar from Decision Resources | |||
Based on our Physician & Payer Forum report entitled Physician and Payer Acceptance of Emerging Fixed-Dose Combination Inhalers for Asthma and COPD, Decision Resources is offering an exclusive webinar entitled Physician and Payer Perspectives on Emerging LABA/ICS Combinations in Asthma and COPD – Will New Treatments Differentiate Themselves from Advair and Symbicort? Because this webinar will feature major report findings, it is ONLY available to purchasers of this report. Please contact us to learn how can purchase this Physician & Payer Forum report and attend the webinar. Fixed-dose combination inhalers, which include long-acting beta2 agonist (LABA)/inhaled corticosteroid (ICS) combinations, are among the most widely prescribed agents for the treatment of asthma and chronic obstructive pulmonary disease (COPD). Two LABA/ICS combinations, GlaxoSmithKline’s Advair and AstraZeneca’s Symbicort, currently dominate the asthma and COPD drug markets. In fact, Advair was the top-selling agent in both markets in 2008, with combined U.S. sales for these two indications totaling more than $4 billion. However, the number of LABA/ICS combinations marketed in the United States is expected to increase from two to six by the end of 2013. As a result of these product launches in the next few years, established brands will see their market share threatened by emerging therapies offering new dosing schedules and devices—however, newcomers to the market must demonstrate to physicians that they offer unique value. Decision Resources surveyed 70 pulmonologists, 70 PCPs, and 21 managed care organization (MCO) pharmacy directors to assess the current use of fixed-dose combination inhalers in the United States and to gauge physicians’ expectations regarding the potential of emerging brands that will penetrate these markets. This webinar, presented by Decision Resources Analyst Benjamin Guikema, Ph.D., will answer the following questions:
Dr. Guikema will conduct a live Q & A session after the presentation. Registration Physician and Payer Perspectives on Emerging LABA/ICS Combinations in Asthma and COPD – Will New Treatments Differentiate Themselves from Advair and Symbicort? May 26, 2010 at 10 a.m. U.S. Eastern Time, 4 p.m. Central European Time (Paris). To learn how you can purchase this Physician & Payer Forum report and attend the webinar, please contact us using the information below. In North America — Keith Rourke at 781-296-2656 or krourke@dresources.com |
|
||
Terms of Use | Privacy Policy | Contact Us | Careers |
|||
Benjamin Guikema, Ph.D., is an analyst in the immune and inflammatory disorders group of Decision Resources. Prior to joining the company, he was a postdoctoral research fellow at the Center for Experimental Therapeutics and Reperfusion Injury at Brigham and Women’s Hospital, a Harvard Medical School affiliate institution. As a research fellow, he obtained a National Research Service Award from the National Institutes of Health for his work on the role of the complement system of innate immunity in ischemia/reperfusion injury. Dr. Guikema received his Ph.D. in cardiovascular science from Albany Medical College in 2005.